Healthcare company PruittHealth said on Friday that its chairman and CEO Neil L. Pruitt Jr. has been elected to serve on a new, independent coronavirus commission for the comprehensive assessment of the nursing home response to the COVID-19 pandemic.
On 14 May 2020, The Centers for Medicare & Medicaid Services (CMS) announced the formation of the Coronavirus Commission for Safety and Quality in Nursing Homes in the US. MITRE, an independent, not-for-profit organization, is standing up the commission and facilitating its activities and will independently author and deliver a report on the commission's findings and recommendations to CMS on 1 September.
The Coronavirus Commission will identify rapid and effective identification and mitigation of transmission of COVID-19 and other infectious diseases nursing homes, recommend rigorous infection control practices and facility resiliency, improve care delivery and responsiveness to the needs of all nursing home residents during emergency, improve existing infection control policies as well as enable coordination across federal surveyors, contractors and state and local entities to mitigate coronavirus and future emergencies.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer